Advances in Dermatology and Allergology
eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current Issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
6/2025
vol. 42
 
Share:
Send email
Share:
Original paper

Comparative efficacy of combined steroid and omalizumab therapy following the surgical treatment of chronic polypous rhinosinusitis in adults

Armen Nazanyan
1, 2, 3
,
Helen Azaryan
4
,
Artur Shukuryan
1, 2, 3
,
Sergey Manasyan
2, 3
,
Kristina Jamalyan
5, 6

  1. Yerevan State Medical University, Yerevan, Armenia
  2. Shengavit Medical Center, Yerevan, Armenia
  3. Astghik Medical Center, Yerevan, Armenia
  4. Helios Medical Center, Yerevan, Armenia
  5. National Institute of Health, Yerevan, Armenia
  6. Erebuni Medical Center, Yerevan, Armenia
Adv Dermatol Allergol 2025; XLII (6): 557–564
DOI: https://doi.org/10.5114/ada.2025.157986
Online publish date: 2026/01/12
Article file
- Comparative efficacy.pdf  [0.16 MB]
Get citation
 
 
1. Cho SH, Hamilos DL, Han DH, Laidlaw TM. Phenotypes of chronic rhinosinusitis. J Allergy Clin Immunol Pract 2020; 8: 1505-11.
2. Sedaghat AR, Kuan EC, Scadding GK. Epidemiology of chronic rhinosinusitis: prevalence and risk factors. J Allergy Clin Immunol Pract 2022; 10: 1395-403.
3. Wang X, Sima Y, Zhao Y, et al. Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors. J Allergy Clin Immunol 2023; 151: 458-68.
4. Mullol J, Azar A, Buchheit KM, et al. Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era. J Allergy Clin Immunol Pract 2022; 10: 1434-53.e9.
5. Gevaert P, Desrosiers M, Cornet M, et al.; ANCHOR-1 and ANCHOR-2 trial investigators. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet 2025; 405: 911-26.
6. Hopkins C, Han JK, Fokkens W, et al. Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison. J Allergy Clin Immunol Pract 2024; 12: 3393-401.e15.
7. Huang ZQ, Liu J, Sun LY, et al. Updated epithelial barrier dysfunction in chronic rhinosinusitis: targeting pathophysiology and treatment response of tight junctions. Allergy 2024; 79: 1146-65.
8. Backaert W, Steelant B, Wils T, et al. Nasal hyperreactivity in allergic rhinitis and chronic rhinosinusitis with polyps: a role for neuronal pathways. Rhinology 2024; 62: 299-309.
9. Huang WH, Hung YW, Hung W, et al. Murine model of eosinophilic chronic rhinosinusitis with nasal polyposis inducing neuroinflammation and olfactory dysfunction. J Allergy Clin Immunol 2024; 154: 325-39.e3.
10. Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 2023; 61: 194-202.
11. Eschenbacher W, Straesser M, Knoeddler A, et al. Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis. Immunol Allergy Clin North Am 2020; 40: 539-47.
12. Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy 2021; 14: 127-34.
13. De Prado Gomez L, Khan AH, Peters AT, et al. Efficacy and safety of dupilumab versus omalizumab in chronic rhinosinusitis with nasal polyps and asthma: EVEREST trial design. Am J Rhinol Allergy 2022; 36: 788-95.
14. Chong LY, Piromchai P, Sharp S, et al. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev 2021; 3: CD013513.
15. Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 2022; 10: 2695-709.
16. De Corso E, Pasquini E, Trimarchi M, et al.; Dupireal Italian Study Group. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL). Allergy 2023; 78: 2669-83.
17. Papacharalampous GX, Constantinidis J, Fotiadis G, et al. Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents’ efficacy. Int Forum Allergy Rhinol 2024; 14: 96-109.
18. Miglani A, Soler ZM, Smith TL, et al. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis. Int Forum Allergy Rhinol 2023; 13: 116-28.
19. Dejaco D, Riedl D, Huber A, et al. The SNOT-22 factorial structure in European patients with chronic rhinosinusitis: new clinical insights. Eur Arch Otorhinolaryngol 2019; 276: 1355-65.
20. Snidvongs K, Dalgorf D, Kalish L, et al. Modified Lund Mackay Postoperative Endoscopy Score for defining inflammatory burden in chronic rhinosinusitis. Rhinology 2014; 52: 53-9.
21. Likness MM, Pallanch JF, Sherris DA, et al. Computed tomography scans as an objective measure of disease severity in chronic rhinosinusitis. Otolaryngol Head Neck Surg 2014; 150: 305-11.
22. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013; 131: 110-6.e1.
23. Lee KI, Ryu G, Yoo SH, et al.; Korean Rhinologic Society. Biologics for chronic rhinosinusitis with nasal polyps: current status and clinical considerations in Korea. J Rhinol 2025; 32: 1-9.
24. Han JK, Bachert C, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP (LIBERTY NP SINUS-24 and SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394: 1638-50.
25. Bachert C, Han JK, Desrosiers M, et al. Dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): a pooled analysis. Allergy 2021; 76: 302-19.
26. Gevaert P, Omachi TA, Corren J, et al. Efficacy of biologics in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 2020; 8: 1485-95.e6.
27. Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe CRSwNP patients treated with mepolizumab: SYNAPSE study results. J Allergy Clin Immunol 2021; 147: 951-61.
28. Laidlaw TM, Mullol J, Fan C, et al. Efficacy and safety of benralizumab in patients with severe CRSwNP: results from the OSTRO phase 3 trial. J Allergy Clin Immunol 2022; 149: 1309-17.e1.
29. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368: 924-35.
30. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-15.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Bentus.